Tag: I-Factor
i-FACTOR peptide enhanced bone graft is cost-effective compared to local autograft...
Cerapedics has announced the publication of the results of a study to evaluate the cost-effectiveness of i-FACTOR peptide enhanced bone graft compared to autograft...
IVANOS study reveals i-FACTOR bone graft use more than doubles fusion...
Level 1 evidence, presented at EUROSPINE 2018 in Barcelona, Spain, demonstrates that i-FACTOR peptide enhanced bone graft results in significantly higher rates of fusion...
Cerapedics announces closing of US$22 million financing
Cerapedics has announced that the company completed a US$22 million financing led by KCK Group, a family investment fund that focuses on innovative medical...
Use of i-FACTOR peptide enhanced bone graft more than doubles fusion...
The use of i-FACTOR peptide enhanced bone graft (Cerapedics) resulted in a 50% fusion rate, compared to a 20% fusion rate using allograft in...
i-FACTOR™: Small peptide, big impact
This article is sponsored by Cerapedics, Inc.
A FAST, RELIABLE AND PROVEN ALTERNATIVE TO AUTOGRAFT
i-FACTOR peptide-enhanced bone graft is challenging the gold standard in bone...
Peptide-enhanced bone graft outperforms autograft at two years
A prospective, multicentre trial has found that a peptide-enhanced bone graft is non-inferior compared to local autograft bone. In addition, the bone graft outperformed...
Two-year results show statistical superiority of Cerapedics’ I-Factor to autograft in...
Cerapedics has announced the publication of two-year follow-up data from a US Food and Drug Administration (FDA) Investigational Device Exemption (IDE) clinical trial of...
Cerapedics awarded group purchasing agreement with Premier for I-Factor
Cerapedics has been awarded a group purchasing agreement with Premier, a healthcare improvement company.
The new agreement allows Premier members, at their discretion, to take...